-
2023-06-27
Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
Verona Pharma plc (Nasdaq: VRNA) announces the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of
-
2023-04-10
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
Verona Pharma plc (Nasdaq: VRNA) announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE - China Phase 3 trial for the maintenance treatment of COPD
- 1
Contact PR
